Blurbs

Robert W. Baird Gives a Buy Rating to Marinus (MRNS)

In a report released on August 11, Brian Skorney from Robert W. Baird assigned a Buy rating to Marinus (MRNSResearch Report), with a price target of $32.00. The company’s shares closed yesterday at $5.68.

According to TipRanks, Skorney is an analyst with an average return of -4.1% and a 46.53% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Biogen, and Neurocrine.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $24.50 average price target, which is a 331.34% upside from current levels. In a report released on August 12, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $17.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Marinus’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.79 million and a GAAP net loss of $39.43 million. In comparison, last year the company earned a revenue of $1.91 million and had a GAAP net loss of $23.82 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Read More on MRNS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos